Welcome to Stoneprime US, a trailblazer in the intersection of finance, biotech, and Artificial Intelligence. We develop both qualitative and quantitative AI algorithms to replace and automate the job of scientific analysts, assessing the potential development of biotech companies in the US stock market.
Whether you’re an institutional investor, a High Net Worth Individual, a Family Office or a Venture Capital, Stoneprime US offers a unique investment experience that combines the dynamism of biotech and the accuracy of Artificial Intelligence.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
Adopting a unique AI – driven strategy, we invest in biotech firms based on potential FDA drug approvals. Harnessing the power of AI, we delve deep into market reactions to new discoveries.
Qualitative AI represents the core of our algorithms. Our technology allows us to examine resources, capabilities and CV’s of the target companies’ management team. We also assess their quality or research analyzing molecules, competitors, congress abstracts, published papers, and scientific citations.
Quantitative AI tries to find the ideal entry point for the examined stock. The code individualizes micro-patterns in the stock movement, needed to fully capture the movement. We examine the profile of each individual asset from multiple perspectives, searching for clues invisible to the human eye with an innovative scientific approach.